Shots:

• Amgen enters into collaboration with Qiagen to develop tissue-based CDx leveraging its Therascreen platform for its investigational AMG 510- identifying patients with KRAS G12C mutation and collaborates with Guardant Health to develop a liquid biopsy CDx identifying patients with actionable alteration in NSCLC
• Qiagen and Guardant Health will seek regulatory approval including PMA form the US FDA for their respective tests. The agreement with both companies will initially focus on CDx tests for NSCLC and allow the further development of a test for Amgen’s other clinical program
• AMG 510 is an investigational KRAS(G12C) inhibitor and has received FDA’s ODD for previously treated mNSCLC and colorectal cancer with KRAS G12C mutation and FT designation for mNSCLC with KRAS G12C mutation

Click here to­ read full press release/ article | Ref: Amgen | Image: Life Science Consultant